Metagenomi Therapeutics’ September 2026 presentation puts cash at $120.7 million at the end of Q2 2026 and anticipates funding operations through Q4 2027. For investors, the stated runway sets a timetable around MGX-001’s progress toward the clinic and the company’s broader gene-editing plans.
Key Highlights
- Metagenomi Therapeutics anticipates its cash runway will support operations through Q4 2027.
- MGX-001 is advancing toward the clinic as a potential one-time treatment for hemophilia A.
- The presentation places annual hemophilia A treatment costs at ~$565K - $750K and lifetime costs at ~$18M - $24M.
Metagenomi Therapeutics, Inc. (NASDAQ: MGX) is a Pharmaceuticals: Major company. Its September 2026 corporate presentation lists $120.7 million in cash at the end of Q2 2026 and anticipates that funding will support operations through Q4 2027. The company is advancing MGX-001 toward the clinic for hemophilia A, with development centred on a defined clinical path and endpoints. The program is designed as a potentially durable, one-time curative treatment that uses gene editing to integrate a Factor VIII gene at the albumin locus. Its wider plans include potential work in neuromuscular and liver disease targets, alongside Business development for cell-therapy applications.
MGX-001 Targets Hemophilia A Treatment Burden
The presentation identifies roughly 25,000 hemophilia A patients in the United States and describes the condition as a blood-clotting disease linked to loss of functional Factor VIII. The filing says repeated bleeding can cause progressive joint damage, inflammation and pain. Current care includes Factor VIII replacement and non-factor bispecific treatment, while the latter is described as offering only ~10-15% FVIII-equivalent protection and may require supplementation for serious injury or surgery. The presentation lists annual treatment costs of ~$565K - $750K and lifetime costs of ~$18M - $24M.



Please wait processing your request...